Press Release 14 Jun 2013

Dublin June 14th 2013- Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO, Isao Teshirogi, Ph.D.; hereafter “Shionogi” or “the Company”) announces that it has entered into an Agreement with Irish research institutions on the formation of an international network for industry-academic collaboration in research and development.

By signing this Agreement, Shionogi will implement in Ireland the Shionogi Science Program, which the Company is working on as part of its globalization of industry-university collaboration. In addition, Shionogi will gradually expand the network, and exchange with academic human resources in Ireland, and further push forward with the globalization of industry-university collaboration.

As one of specific initiatives, Shionogi has already separately signed Memorandum of Understanding to carry out broad-ranging information exchanges and personnel exchanges in research and development with the six universities named below.

  •  National University of Ireland, Galway
  •  National University of Ireland, Maynooth
  •  University College Dublin
  •  University of Limerick
  •  Royal College of Surgeons
  •  Trinity College, Dublin

Main points agreed on
1. With the cooperation of Ireland Embassy, establish a cooperative research relationship whereby Shionogi matches the seeds of research organizations in Irish universities with its drug-discovery technology and needs for drug discovery, and carry out joint research on items that match.

2. Promote personnel exchange with research organizations in universities in Ireland as Shionogi aim to develop international human resources.

Barry O’Leary, CEO, IDA Ireland.
I welcome this collaborative initiative between Shionogi & Co. Ltd and IDA Ireland. Ireland has a globally significant Life Science sector and is home to nine of the top ten world’s leading pharmaceutical and biotechnology companies. The signing of this Memorandum of Understanding will strengthen Ireland’s business ties and open doors to attract further Japanese investment. To be chosen as Shionogi’s partner in the MoU will heighten Ireland’s reputation as a global leader in the pharmaceutical and biotechnology sector.

Minister Sherlock TD, Minister of State, Department of Enterprise, Jobs & Innovation and Department of Education & Skills with responsibility for Research & Innovation
I am pleased to see this combined initiative between Shionogi & Co Ltd and Ireland with the signing of this Memorandum of Understanding. Ireland has a strong and established Life Science industry, with research and development the primary activity carried out in Ireland. We look forward to supporting Shionogi & Co. Ltd partner with Irish Universities to reap the rewards of this initiative. 

Isao Teshirogi, Ph.D., President and Representative Director, Shionogi & Co., Ltd.
The signing of contracts with Irish Universities on the formation of an international network for industry-academic collaboration in research and development is extremely significant for Shionogi. In Ireland, with the strong leadership of the government, academia actively promotes research and development in life-science and biotechnology area in close relationship with the industries. In addition, Ireland has achieved strong growth because of many of the world’s leading pharmaceutical companies and biotechnology companies are expanding their business into Ireland.

The opportunity to form cooperative research relationships and engage in joint research with Irish research intuitions will help enhance our research and development capabilities and enable personnel exchanges that are ideal for development of international human resources. As a pharmaceutical company that aims to contribute globally, we are extremely honored to have this opportunity and expect it to prove of great significance. Taking an advantage of this opportunity, we will accelerate our globalization based on research and development.
 
Reference
Shionogi &Co., Ltd.
Headquartered in Osaka, Japan, Shionogi & Co., Ltd. is a major research-driven pharmaceutical company dedicated to placing the highest value on patients Shionogi’s Research and Development currently targets three therapeutic areas: Infectious Disease, Pain, and Metabolic Syndrome. The Company is the originator of innovative medicines which have been successfully delivered to millions of patients worldwide. In patients around the world through development in these therapeutic areas is Shionogi’s primary goal. For more details, please visit

IDA Ireland
Foreign Direct Investment in Ireland
IDA Ireland (IDA) is the Irish Government’s Foreign Direct Investment Agency. The function of IDA is to contribute to Ireland’s economy by securing new investment from foreign and multinational companies and through developing the strong base of 1,000 overseas companies already located here in a variety of business sectors including:                     

  •     Life Sciences
  •     Information Communications Technology (ICT)
  •     International Financial Services
  •     Globally Traded Business

Global competition for FDI is relentless and it is the responsibility of IDA to ensure Ireland continues to attract premium mobile foreign investment. IDA continues to secure high end value added investments in support of national and regional economic development.

Ireland as a base for FDI has changed from being primarily a manufacturing base to becoming the home to top tier investments from the world’s leading corporations. Global Services, Research, Development, Innovation and High-Tech Manufacturing are the areas that now go hand in hand with what Ireland can offer foreign investors.

IDA Ireland focuses on encouraging collaboration between academic institutions and corporations, improving infrastructure and working closely with sister enterprise agencies for the fast implementation of change in order to generate further FDI and to ensure existing clients continue to develop their operations here.

SHIONOGI Science Program
The SHIONOGI Science Program is based on the company policy to: “Constantly strive to provide medicine of the best possible kind essential for protection of the health of the people”. Under this basic policy we are making a serious effort to have collaboration between industry and academia so that we can identify novel drug seeds globally and develop them into superior pharmaceuticals, as we aim to continue providing excellent pharmaceutical products to many people. This program began in the UK in 2011, and in 2012, we expanded the program to seven countries: Australia, Belgium, Denmark, Japan, Luxembourg, the Netherlands, and the United Kingdom. This year, we are going to operate the program in 10 countries, including Ireland, Germany and France in addition to the previous seven countries. Since fiscal 2007, Shionogi has presented its needs under the name of FINDS (Pharma-Innovation Discovery competition Shionogi) and got many innovative ideas from researchers in Japan to put the ideas into practical use while working together.

Forward-looking Statements
This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For further information, contact:
Shionogi & Co., Ltd. - Corporate Communications Department
Osaka Telephone: +81-6-6209-7885 Fax: +81-6-6229-9596
Tokyo Telephone: +81-3-3406-8164 Fax: +81-3-3406-8099

IDA Ireland - Corporate Communications Department
Fidelma Geraghty, IDA Ireland, +353-1-6034127, Fidelma.Geraghty@ida.ie
 

Contact us

Contact IDA Ireland

You'll find us responsive to your needs, proactive, professional and willing to go the extra mile.

Contact IDA Ireland

International Offices

We have 28 Offices worldwide helping support companies expand their operations in Ireland.

Find your nearest office